Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (771-780 of 831) with videos related to

Pageof 84
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Cell Reports|March 30, 2021
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replicationGustavo Garcia, Arun Sharma, Arunachalam Ramaiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2014
Detection of cancer DNA in plasma of patients with early-stage breast cancerJulia A Beaver, Danijela Jelovac, Sasidharan Balukrishna, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2005
Breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et alIngrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 19, 2007
Invasive breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Pageof 84

Showing results (771-780 of 831) with videos related to

Sort By:
Pageof 84
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02S A Hurvitz, S Loi, J O'Shaughnessy, et al.
Cell Reports|March 30, 2021
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replicationGustavo Garcia, Arun Sharma, Arunachalam Ramaiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2014
Detection of cancer DNA in plasma of patients with early-stage breast cancerJulia A Beaver, Danijela Jelovac, Sasidharan Balukrishna, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2005
Breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et alIngrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSara M Tolaney, Hao Guo, Sonia Pernas, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 19, 2007
Invasive breast cancerRobert W Carlson, Benjamin O Anderson, Harold J Burstein, et al.
Pageof 84